Mahmoud Rami H, Mahmoud Omar, Biazus Soares Georgia, Yosipovitch Gil
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, 5555 Ponce de Leon, Coral Gables, FL, 33146, USA.
Dermatol Ther (Heidelb). 2024 Apr;14(4):829-840. doi: 10.1007/s13555-024-01144-w. Epub 2024 Apr 13.
The experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to manage their conditions without many of the systemic side effects of non-topical therapies. We review a multitude of new topical medications targeting the skin, immune system, and neural receptors. The list includes Janus kinase inhibitors, tyrosine kinase inhibitors, phosphodiesterase inhibitors, transient receptor vanilloid inhibitors, topical cannabinoids, and topical acetaminophen. Many of the topical therapies reviewed show promising data in phase 2-3 clinical trials, but further research is needed to compare therapies head-to-head and test their efficacy on a broader range of conditions.
瘙痒的体验常常给患者的生活质量带来负担，并可能造成巨大痛苦。局部治疗是许多皮肤和全身性疾病治疗的主要手段，使患者有机会在不产生许多非局部治疗的全身性副作用的情况下控制病情。我们综述了多种针对皮肤、免疫系统和神经受体的新型局部用药。其中包括 Janus 激酶抑制剂、酪氨酸激酶抑制剂、磷酸二酯酶抑制剂、瞬时受体香草酸抑制剂、局部用大麻素和局部用对乙酰氨基酚。所综述的许多局部治疗方法在 2-3 期临床试验中显示出有前景的数据，但需要进一步研究以进行疗法之间的直接比较，并在更广泛的病症上测试其疗效。
